The Contribution of Gi/o Protein to Opioid Antinociception in an Oxaliplatin-Induced Neuropathy Rat Model

Abstract.: Oxaliplatin is a chemotherapeutic agent that induces chronic refractory neuropathy. To determine whether opioids effectively relieve this chronic neuropathy, we investigated the efficacies of morphine, oxycodone, and fentanyl, and the mechanisms underlying opioid antinociception, in oxali...

Full description

Saved in:
Bibliographic Details
Main Authors: Tomoe Kanbara (Author), Atsushi Nakamura (Author), Keiko Takasu (Author), Koichi Ogawa (Author), Masahiro Shibasaki (Author), Tomohisa Mori (Author), Tsutomu Suzuki (Author), Minoru Hasegawa (Author), Gaku Sakaguchi (Author), Toshiyuki Kanemasa (Author)
Format: Book
Published: Elsevier, 2014-04-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_b372741afd934b13a488b7b5d4c7b3d6
042 |a dc 
100 1 0 |a Tomoe Kanbara  |e author 
700 1 0 |a Atsushi Nakamura  |e author 
700 1 0 |a Keiko Takasu  |e author 
700 1 0 |a Koichi Ogawa  |e author 
700 1 0 |a Masahiro Shibasaki  |e author 
700 1 0 |a Tomohisa Mori  |e author 
700 1 0 |a Tsutomu Suzuki  |e author 
700 1 0 |a Minoru Hasegawa  |e author 
700 1 0 |a Gaku Sakaguchi  |e author 
700 1 0 |a Toshiyuki Kanemasa  |e author 
245 0 0 |a The Contribution of Gi/o Protein to Opioid Antinociception in an Oxaliplatin-Induced Neuropathy Rat Model 
260 |b Elsevier,   |c 2014-04-01T00:00:00Z. 
500 |a 1347-8613 
500 |a 10.1254/jphs.14133FP 
520 |a Abstract.: Oxaliplatin is a chemotherapeutic agent that induces chronic refractory neuropathy. To determine whether opioids effectively relieve this chronic neuropathy, we investigated the efficacies of morphine, oxycodone, and fentanyl, and the mechanisms underlying opioid antinociception, in oxaliplatin-induced neuropathy in rats. Rats exhibited significant mechanical allodynia following 2 weeks of chronic oxaliplatin administration. Within the range of doses that did not induce sedation and/or muscle rigidity, morphine (3 mg/kg, subcutaneously, s.c.) and oxycodone (0.3 - 0.56 mg/kg, s.c.) completely reversed oxaliplatin-induced mechanical allodynia, whereas fentanyl (0.017 - 0.03 mg/kg, s.c.) showed partial antinociception. The antinociception of the optimal doses of morphine and oxycodone were completely inhibited by pertussis toxin (PTX; 0.5 μg/rat, i.c.v.), a Gi/o protein inhibitor, while the partial effect of fentanyl was not affected in the oxaliplatin model. In the [35S]-GTPγS binding assay, activation of μ-opioid receptor by fentanyl, but not by morphine or oxycodone, in the mediodorsal thalamus was significantly reduced in oxaliplatin-treated rats. These results indicate that the lower antinociceptive potency of fentanyl in the oxaliplatin model might in part result from the loss of PTX-sensitive Gi/o protein activation, and the degree of Gi/o protein activation might be related to the potency of antinociception by opioids in this model. Keywords:: opioid, antinociception, oxaliplatin, neuropathy, Gi/o protein 
546 |a EN 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Journal of Pharmacological Sciences, Vol 126, Iss 3, Pp 264-273 (2014) 
787 0 |n http://www.sciencedirect.com/science/article/pii/S1347861319300805 
787 0 |n https://doaj.org/toc/1347-8613 
856 4 1 |u https://doaj.org/article/b372741afd934b13a488b7b5d4c7b3d6  |z Connect to this object online.